Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

Abstract

The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11 – 25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06 µg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06 µg/L had a day-100 all-cause mortality rate of 7% (P < 0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06 µg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.

Keywords:

• Amyloidosis
• multiple myeloma
• restrictive cardiomyopathy
• stem cell transplantation
• troponin T